Walter Fischli - Actelion Senior Vice President Academia Relations

President

Mr. Walter Fischli was Senior Vice President Academia Relations at Actelion Ltd since July 1 2009. He is one of the founders of the Company. He was Member of a research fellowship at Addiction Research Foundation at Stanford University. He has experience in drug discovery at F. HoffmannLa Roche. He served as Head of Drug Discovery Molecular Biology Biochemistry from 1997 till June 2009. He is a Biochemist educated at Edgenoessische Technische Hochschule in Zurich with further training in molecular biology and organic chemistry. since 2009.
Age 64
Tenure 15 years
Phone41 61 565 65 65
Webhttp://www.actelion.com

Actelion Management Efficiency

The company has return on total asset (ROA) of 23.87 % which means that it generated a profit of $23.87 on every $100 spent on assets. This is very large. Similarly, it shows a return on equity (ROE) of 47.08 %, meaning that it generated $47.08 on every $100 dollars invested by stockholders. Actelion's management efficiency ratios could be used to measure how well Actelion manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

PRESIDENT Age

Stephen ButzNoble plc
46
Paul HumphriesFlex
61
Michael HartungFlex
55
Charles MathisScanSource
55
Richard BarkerNoble plc
42
Robert EiflerNoble plc
44
Michael WerdannNETGEAR
56
John CarlsonFlex
N/A
Thomas SloanNoble plc
50
Laura CampbellNoble plc
51
Scott OfferFlex
59
Paul BaldassariFlex
N/A
Tamesa RogersNETGEAR
50
Yaniv FriedmanDelek Drilling
42
Adam PeakesNoble plc
44
Scott MarksNoble plc
58
Yosef GvuraDelek Drilling
46
William TurcotteNoble plc
60
Matthew DeanScanSource
N/A
Hooi KwangFlex
N/A
David HenryNETGEAR
51
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. Actelion [ALIOF] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Actelion Leadership Team

Elected by the shareholders, the Actelion's board of directors comprises two types of representatives: Actelion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actelion. The board's role is to monitor Actelion's management team and ensure that shareholders' interests are well served. Actelion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actelion's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Widman, Co-Founder
Christian Albrich, Member of the Management Board, Senior Vice President Head Global Human Resources
Walter Fischli, Senior Vice President Academia Relations
Robert Bertolini, Member of the Board of Directors
Carl Feldbaum, Member of the Board of Directors
Andre Muller, Member of the Management Board, CFO, Executive Vice President
John Greisch, Director
Rudi Frank, Senior Vice President Head Global Quality Management, Member of the Extended Executive Committee
Marian Borovsky, Sr. VP, Group General Counsel and Corporate Secretary
Werner Henrich, Member of the Board of Directors
Nicholas Franco, Member of the Management Board, Executive Vice President Chief Business Development Officer
Martine Clozel, Founder, Chief Scientific Officer, Head of Drug Discovery Pharmacology and Preclinical Devel. and Sr. VP
Juhani Anttila, Member of the Board of Directors
JeanPierre Garnier, Chairman of the Board of Directors
David Stout, Member of the Board of Directors
JeanPaul Clozel, CEO, Member of the Executive Committee, Delegate to the Board of Directors
Guy Braunstein, Member of the Management Board, Executive Vice President Head of Clinical Development
Andrew Weiss, Head of Investor Relations and Corporate Communications and Sr. VP
Herna Verhagen, Member of the Board of Directors
Michael Jacobi, Member of the Board of Directors
Jean Malo, Member of the Board of Directors
Otto Schwarz, COO and Executive VP
Roland Haefeli, Member of the Management Board, Senior Vice President Head of Investor Relations & Public Affairs
Thomas Weller, Vice President Co-Head of Drug Discovery
Peter Gruss, Member of the Board of Directors

Actelion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Actelion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Actelion in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Actelion's short interest history, or implied volatility extrapolated from Actelion options trading.

Pair Trading with Actelion

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Actelion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actelion will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Texas Instruments could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Texas Instruments when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Texas Instruments - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Texas Instruments Incorporated to buy it.
The correlation of Texas Instruments is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Texas Instruments moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Texas Instruments moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Texas Instruments can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Other Consideration for investing in Actelion OTC Stock

If you are still planning to invest in Actelion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Actelion's history and understand the potential risks before investing.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Global Correlations
Find global opportunities by holding instruments from different markets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities